ストックスクリーナーアプリを入手
10.67
1.11%
-0.28
Urogen Pharma Ltd (URGN) 最新ニュース
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Rating of “Buy” from Brokerages - Defense World
(URGN) Long Term Investment Analysis - news.stocktradersdaily.com
UroGen Pharma Ltd. (NASDAQ:URGN) Shares Sold by JPMorgan Chase & Co. - Defense World
AUA hoorays in bladder cancer for J&J, Urogen, more - BioWorld MedTech
UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - Business Wire
It makes sense and dollars to buy UroGen Pharma Ltd (URGN) stock - Sete News
Market Highlights: UroGen Pharma Ltd (URGN) Ends on a High Note at 11.64 - DWinneX
Legal & General Group Plc Boosts Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
HC Wainwright Predicts UroGen Pharma Q1 Earnings - Defense World
UroGen Pharma’s (URGN) Buy Rating Reaffirmed at Guggenheim - American Banking and Market News
Guggenheim Reaffirms Buy Rating for UroGen Pharma (NASDAQ:URGN) - Defense World
Should investors be concerned about UroGen Pharma Ltd (URGN)? - uspostnews.com
Examining the Potential Price Growth of UroGen Pharma Ltd (URGN) - knoxdaily.com
UroGen Pharma Ltd Inc. (URGN) Price Performance: The Role of Supply and Demand - investchronicle.com
Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last? - Yahoo
Renaissance Technologies LLC Makes New Investment in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from D. Boral Capital - Defense World
UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from HC Wainwright - Defense World
Biotech Firm Uncovers Long-Term Cancer Breakthrough in Nevada - streetwisereports.com
UroGen Pharma (URGN) Reports Positive Safety Outcomes in Cancer Study | URGN Stock News - GuruFocus
Let’s Start With The Stock Forecast For UroGen Pharma Ltd (NASDAQ: URGN) - Marketing Sentinel
UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates - Benzinga
UroGen Pharma (URGN) Reports Nearly Four-Year Response Duration for JELMYTO | URGN Stock News - GuruFocus
URGN: UroGen Pharma's UGN-102 Demonstrates Promising Results in Bladder Cancer Treatment | URGN Stock News - GuruFocus
UroGen Pharma Reports Nearly 4-Year Response for Urothelial Cancer Therapy -- Shares Up Pre-Bell - marketscreener.com
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC - ADVFN
UroGen Pharma (URGN) Updates Promising Results from UGN-102 Tria - GuruFocus
UroGen Pharma (URGN) Reports Promising Long-Term Results for Bla - GuruFocus
OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Durat - GuruFocus
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show - GuruFocus
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Dem - GuruFocus
OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment - Yahoo
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC - ADVFN
UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers - ADVFN
UroGen Announces Updated 18-Month Duration of Response (DOR) of - GuruFocus
UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) - Yahoo Finance
UroGen Pharma Announces Encouraging Results from a Phase 1 Dose- - GuruFocus
UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer - Business Wire
UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer | URGN Stock News - GuruFocus
How should investors view UroGen Pharma Ltd (URGN)? - uspostnews.com
Wells Fargo & Company MN Boosts Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma Ltd [URGN] stock for 50,698 USD was sold by Schoenberg Mark - knoxdaily.com
Closing Figures: UroGen Pharma Ltd (URGN)’s Positive Finish at 10.20, Up 1.49 - DWinneX
The Goldman Sachs Group Cuts UroGen Pharma (NASDAQ:URGN) Price Target to $16.00 - Defense World
UroGen Pharma (NASDAQ:URGN) Research Coverage Started at Scotiabank - Defense World
Alliancebernstein L.P. Buys 175,859 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Scotiabank Initiates UroGen Pharma at Sector Outperform With $23 Price Target - marketscreener.com
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
UroGen Announces Data Presentations at the American Urological A - GuruFocus
Wellington Management Group LLP Boosts Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Major Breakthrough: UroGen to Reveal 18-Month Cancer Treatment Data at Leading Urology Conference - Stock Titan
UroGen Pharma Ltd. (NASDAQ:URGN) Receives $38.20 Average Target Price from Analysts - The AM Reporter
1.72%
0.85%
大文字化:
|
ボリューム (24 時間):